Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of ASP6294 in female patients with bladder pain syndrome/interstitial cystitis
2016-004138-12Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Jul 2017
- Modality
- Fab Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Interstitial Cystitis-Bladder Pain Syndrome (IC/BPS) comparing ASP6294 with Placebo (2 arms). Primary endpoint: Primary efficacy. Started Jul 2017; status: completed.
02
Drugs
ASP6294
03
Conditions
Interstitial Cystitis-Bladder Pain Syndrome (IC/BPS)
Beyond the preview
Go deeper on 2016-004138-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004138-12.